Literature DB >> 8568672

Inhibition of calcium currents and exocytosis by Lambert-Eaton syndrome antibodies in human lung cancer cells.

M P Viglione1, T J O'Shaughnessy, Y I Kim.   

Abstract

1. Human small-cell lung cancer (SCLC) cells are believed to express the antigens responsible for the production of pathological antibodies in the Lambert-Eaton syndrome (LES), a Ca2+ channel disorder in which quantal transmitter release from the motor nerve terminal is impaired. Whole-cell patch-clamp techniques were used to study the voltage-dependent Ca2+ channels expressed by H146 SCLC cells and the effects of LES antibodies on these channels. The types of Ca2+ channels were determined using biophysical properties and pharmacological sensitivity to several antagonists. 2. Whole-cell Ca2+ currents (ICa) in SCLC cells are sensitive to the dihydropyridine (DHP) nicardipine, omega-conotoxin GVIA (omega-CgTX GVIA) and omega-agatoxin IVA (omega-AgTX IVA). Nicardipine at 100 nM and 10 microM reduced ICa by 35 and 45% (n = 38 cells), respectively, while omega-CgTX GVIA (1 microM) inhibited ICa by 32% (n = 31). Application of omega-AgTX IVA at 50 and 100 nM to the cancer cells decreased ICa by 41 and 42%, respectively (n = 22). 3. Measurement of cell membrane capacitance (Cm) revealed that Ca(2+)-dependent exocytosis underlies the secretory activity of SCLC cells. Exocytosis, when induced by step depolarizing pulses and measured by increases in Cm, was markedly inhibited by nicardipine (10 microM) and omega-AgTX IVA (100 nM). In contrast, omega-CgTX GVIA (1 microM) was not as effective in altering increases in Cm. 4. From negative (-80 mV) and depolarized (-40 mV) holding potentials, both peak and plateau ICa were inhibited by the presence of LES antibodies (1 mg ml-1 IgG). LES serum also reduced depolarization-induced increases in Cm by 48% (n = 15). 5. To determine whether the LES antibodies are downregulating a specific type(s) of Ca2+ channel, nicardipine (10 microM), omega-CgTX GVIA (1 microM) or omega-AgTX IVA (100 nM) was applied to tumour cells that had been previously exposed to LES serum for 24 h. The most pronounced change was that omega-AgTX IVA was 38-84% less effective at reducing ICa after the IgG treatment. The effectiveness of nicardipine was diminished by 18% after incubation with the LES antibodies, whereas the omega-CgTX GVIA was seen to be more effective. These results suggest that LES IgG downregulates P-type Ca2+ channels and, possibly, to a lesser extent L-type channels. 6. In view of recent evidence that P-type Ca2+ channels mediate cholinergic transmitter release at the mammalian neuromuscular junction (NMJ), the expression of P-type Ca2+ channels in the SCLC cells and the reactivity of LES IgG with these channels support the hypothesis that P-type Ca2+ channels in these cancer cells may trigger the autoantibody production in this disorder. The antibodies so produced are implicated in the functional impairment of the Ca2+ channels characteristic of LES.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8568672      PMCID: PMC1156672          DOI: 10.1113/jphysiol.1995.sp020968

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  34 in total

1.  The isolation of gamma globulin from blood-serum by rivanol.

Authors:  J HOREJSI; R SMETANA
Journal:  Acta Med Scand       Date:  1956-06-30

2.  Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones.

Authors:  T Fukuoka; A G Engel; B Lang; J Newsom-Davis; C Prior; D W Wray
Journal:  Ann Neurol       Date:  1987-08       Impact factor: 10.422

3.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

4.  Dihydropyridine receptors in muscle are voltage-dependent but most are not functional calcium channels.

Authors:  L M Schwartz; E W McCleskey; W Almers
Journal:  Nature       Date:  1985 Apr 25-May 1       Impact factor: 49.962

5.  Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG.

Authors:  Y I Kim
Journal:  Muscle Nerve       Date:  1986 Jul-Aug       Impact factor: 3.217

6.  Electrical excitability of oat cell carcinoma.

Authors:  A S Tischler; M A Dichter; B Biales
Journal:  J Pathol       Date:  1977-07       Impact factor: 7.996

7.  Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse.

Authors:  B Lang; J Newsom-Davis; C Prior; D Wray
Journal:  J Physiol       Date:  1983-11       Impact factor: 5.182

8.  Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line.

Authors:  A Roberts; S Perera; B Lang; A Vincent; J Newsom-Davis
Journal:  Nature       Date:  1985 Oct 24-30       Impact factor: 49.962

9.  A venom peptide with a novel presynaptic blocking action.

Authors:  L M Kerr; D Yoshikami
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

10.  Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma.

Authors:  Y I Kim
Journal:  Muscle Nerve       Date:  1985-02       Impact factor: 3.217

View more
  3 in total

1.  Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells.

Authors:  K L Engisch; M M Rich; N Cook; M C Nowycky
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

2.  Lambert-Eaton syndrome antibodies inhibit acetylcholine release and P/Q-type Ca2+ channels in electric ray nerve endings.

Authors:  Y Satoh; N Hirashima; H Tokumaru; M P Takahashi; J Kang; M P Viglione; Y I Kim; Y Kirino
Journal:  J Physiol       Date:  1998-04-15       Impact factor: 5.182

Review 3.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.